UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis

Journal of the neurological sciences, 2017-01, Vol.372, p.331-341

2017

Volltextzugriff (PDF)

Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis

Neurology, 2015-02, Vol.84 (8), p.776-783

2015

Volltextzugriff (PDF)

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1075-1084

2016

Volltextzugriff (PDF)

Outcome Measures in Clinical Trials for Multiple Sclerosis

CNS drugs, 2017-03, Vol.31 (3), p.217-236

2017

Volltextzugriff (PDF)

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study

Journal of neurology, 2016-07, Vol.263 (7), p.1323-1331

2016

Volltextzugriff (PDF)

Pathway and network-based analysis of genome-wide association studies in multiple sclerosis

Human molecular genetics, 2009-06, Vol.18 (11), p.2078-2090

2009

Volltextzugriff (PDF)

Gray matter damage in multiple sclerosis: Impact on clinical symptoms

Neuroscience, 2015-09, Vol.303, p.446-461

2015

Volltextzugriff (PDF)

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Multiple sclerosis, 2020-12, Vol.26 (14), p.1816-1821

2020

Volltextzugriff (PDF)

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment

Multiple sclerosis, 2020-01, Vol.26 (1), p.23-37

2020

Volltextzugriff (PDF)

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

JAMA neurology, 2019-03, Vol.76 (3), p.274

2019

Volltextzugriff (PDF)

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data

Neurology, 2019-11, Vol.93 (21), p.e1921

2019

Volltextzugriff (PDF)

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

CNS drugs, 2018-06, Vol.32 (6), p.543-558

Uitdehaag, Bernard M. J.

2018

Volltextzugriff (PDF)

Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant

Brain (London, England : 1878), 2016-01, Vol.139 (Pt 1), p.115-126

2016

Volltextzugriff (PDF)

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study

Brain (London, England : 1878), 2018-09, Vol.141 (9), p.2605-2618

2018

Volltextzugriff (PDF)

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Lancet neurology, 2012, Vol.11 (1), p.33-41

2012

Volltextzugriff (PDF)

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method

PloS one, 2016-01, Vol.11 (1), p.e0143942-e0143942

2016

Volltextzugriff (PDF)

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

JAMA neurology, 2021-07, Vol.78 (7), p.880

2021

Volltextzugriff (PDF)

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis

Multiple sclerosis, 2014-04, Vol.20 (4), p.481-488

2014

Volltextzugriff (PDF)

Disruption of structural and functional networks in long-standing multiple sclerosis

Human brain mapping, 2014-12, Vol.35 (12), p.5946-5961

2014

Volltextzugriff (PDF)

Increased default-mode network centrality in cognitively impaired multiple sclerosis patients

Neurology, 2017-03, Vol.88 (10), p.952-960

2017

Volltextzugriff (PDF)

Increased connectivity of hub networks and cognitive impairment in multiple sclerosis

Neurology, 2017-05, Vol.88 (22), p.2107-2114

2017

Volltextzugriff (PDF)

Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis

Neurology, 2019-10, Vol.93 (14), p.e1348

2019

Volltextzugriff (PDF)

A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis

Neurology, 2020-08, Vol.95 (8)

2020

Volltextzugriff (PDF)

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis

Neurology, 2013-01, Vol.80 (1), p.69-75

2013

Volltextzugriff (PDF)

1 – 25 von 423

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(372)
Mit Volltextzugriff
(344)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis

Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Outcome Measures in Clinical Trials for Multiple Sclerosis

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study

Pathway and network-based analysis of genome-wide association studies in multiple sclerosis

Gray matter damage in multiple sclerosis: Impact on clinical symptoms

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis

Disruption of structural and functional networks in long-standing multiple sclerosis

Increased default-mode network centrality in cognitively impaired multiple sclerosis patients

Increased connectivity of hub networks and cognitive impairment in multiple sclerosis

Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis

A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis

Suchergebnisse filtern